Search Results for "loperamide"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for loperamide. Results 21 to 25 of 25 total matches.
In Brief: A New Breast Cancer Indication for Sacituzumab Govitecan (Trodelvy) (online only)
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
diarrhea and loperamide for severe diarrhea
can be considered. One 180-mg vial of Trodelvy
costs about ...
Sacituzumab govitecan-hziy (Trodelvy – Gilead) has
been approved for treatment of unresectable locally
advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2
(HER2)-negative breast cancer in adults who received
prior endocrine therapy and ≥2 additional systemic
therapies for metastatic disease. It was previously
approved for treatment-refractory metastatic triplenegative
breast cancer and for treatment of locally
advanced or metastatic urothelial cancer in adults
who received platinum-based chemotherapy and a
programmed death receptor-1...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):e43-4 doi:10.58347/tml.2023.1671g | Show Introduction Hide Introduction
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
with Diarrhea (IBS-D)
Antidiarrheals such as loperamide (Imodium A-D, and generics)
are effective in reducing ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating. IBS
is classified by its predominant bowel symptom:
constipation (IBS-C), diarrhea (IBS-D), mixed type
(IBS-M), or unclassified (IBS-U). Since the exact cause
of IBS is unknown, the goal of treatment is symptom
control. Some over-the-counter (OTC) products and
prescription drugs for IBS are listed in Tables 1-4. The
safety of these drugs during pregnancy and lactation
is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24 doi:10.58347/tml.2025.1721a | Show Introduction Hide Introduction
Teduglutide Injection (Gattex) for Short Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Apr 15, 2013 (Issue 1414)
diets and administration of IV
fluids, parenteral nutrition, antimotility agents such as
loperamide ...
The FDA has approved teduglutide (te due’ gloo tide;
Gattex – NPS), a recombinant DNA analog of
glucagon-like peptide-2 (GLP-2), for treatment of short
bowel syndrome (SBS) in adults who are dependent
on parenteral support.
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
. Administration
of atropine for early-onset diarrhea and loperamide for
severe diarrhea can be considered. One ...
The FDA has approved sacituzumab govitecan-hziy
(Trodelvy – Immunomedics), a trophoblast cell-surface
antigen-2 (Trop-2)-directed antibody and topoisomerase
inhibitor conjugate, for treatment of adults with metastatic
triple-negative breast cancer who have received ≥2 prior
therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
Management of Opioid Withdrawal Symptoms
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018 (Issue 1554)
with bismuth subsalicylate or the gutspecifi
c opioid loperamide. Abdominal cramping can
be managed ...
Pharmacologic management of opioid withdrawal
symptoms can reduce the intensity of drug craving
and improve treatment retention in patients with opioid
use disorder who will receive maintenance treatment.
Withdrawal management without subsequent maintenance
treatment is associated with high rates of
relapse, overdose death, and HIV and/or hepatitis C
virus infection. Several guidelines on management
of opioid withdrawal are available. Maintenance
treatment of opioid use disorder was reviewed in a
previous issue.